- Home
- VEL vs TRVI Comparison
VEL vs TRVI Comparison
Compare VEL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- TRVI
- Stock Information
- Founded
- VEL 2004
- TRVI 2011
- Country
- VEL United States
- TRVI United States
- Employees
- VEL N/A
- TRVI N/A
- Industry
- VEL Finance: Consumer Services
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- VEL Finance
- TRVI Health Care
- Exchange
- VEL Nasdaq
- TRVI Nasdaq
- Market Cap
- VEL 680.6M
- TRVI 725.7M
- IPO Year
- VEL 2020
- TRVI 2019
- Fundamental
- Price
- VEL $18.78
- TRVI $5.46
- Analyst Decision
- VEL Buy
- TRVI Strong Buy
- Analyst Count
- VEL 5
- TRVI 8
- Target Price
- VEL $21.20
- TRVI $19.31
- AVG Volume (30 Days)
- VEL 210.9K
- TRVI 2.6M
- Earning Date
- VEL 07-31-2025
- TRVI 08-07-2025
- Dividend Yield
- VEL N/A
- TRVI N/A
- EPS Growth
- VEL 14.80
- TRVI N/A
- EPS
- VEL 1.94
- TRVI N/A
- Revenue
- VEL $177,987,000.00
- TRVI N/A
- Revenue This Year
- VEL N/A
- TRVI N/A
- Revenue Next Year
- VEL $32.82
- TRVI N/A
- P/E Ratio
- VEL $9.69
- TRVI N/A
- Revenue Growth
- VEL 39.36
- TRVI N/A
- 52 Week Low
- VEL $16.12
- TRVI $2.36
- 52 Week High
- VEL $20.98
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- VEL 63.92
- TRVI 38.66
- Support Level
- VEL $18.46
- TRVI $5.53
- Resistance Level
- VEL $19.50
- TRVI $5.96
- Average True Range (ATR)
- VEL 0.52
- TRVI 0.33
- MACD
- VEL 0.04
- TRVI -0.08
- Stochastic Oscillator
- VEL 74.37
- TRVI 8.46
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.